Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Cardiovasc Intervent Radiol ; 42(10): 1380-1390, 2019 Oct.
Article in English | MEDLINE | ID: mdl-31286197

ABSTRACT

PURPOSE: This study intended to assess effectiveness and safety of the drug-coated balloon (DCB) angioplasty of infrapopliteal atherosclerotic lesions in patients with critical limb ischaemia (CLI) in a real-world setting. METHODS: Consecutive patients with critical limb ischaemia who underwent infrapopliteal drug-coated balloon angioplasty with the ELUTAX SV DCB were enrolled into the prospective, multicentre, single-arm observational registry. Primary outcome was clinical improvement at 6 and 12 months. Secondary outcomes were change in quality of life, primary patency, freedom from repeat revascularisation, and amputation-free survival at 6 and 12 months. RESULTS: A total of 164 patients (74.7 ± 9.2 years) with CLI were included at nine German sites between November 2015 and September 2017. The majority (79.9%) of patients had diabetes mellitus, 57.3% had renal insufficiency, and 35.3% had coronary artery disease. Mean lesion length was 71.2 ± 76.5 mm. The Rutherford category improved by 3.0 ± 2.0 (p < 0.0001) within 12 months, resulting in a clinical improvement by at least one Rutherford category in 80.2% of the patients. Walking impairment questionnaire score, European Quality of Life index, and patient-reported pain improved significantly from baseline to 6 and 12 months. Primary patency was 68.5%, freedom from target lesion revascularisation 90.6%, and amputation-free survival 83.5% at 12 months. CONCLUSION: Infrapopliteal drug-coated balloon angioplasty with the ELUTAX SV DCB in patients with critical limb ischaemia was efficacious and safe over the medium term. The study is registered with Clinical.Trials.gov (Identifier: NCT02539940).


Subject(s)
Angioplasty, Balloon/methods , Ischemia/etiology , Ischemia/therapy , Peripheral Arterial Disease/complications , Peripheral Arterial Disease/therapy , Popliteal Artery/pathology , Aged , Cardiovascular Agents , Coated Materials, Biocompatible , Female , Germany , Humans , Ischemia/pathology , Kaplan-Meier Estimate , Male , Peripheral Arterial Disease/pathology , Prospective Studies , Time Factors , Treatment Outcome , Vascular Patency
2.
JACC Cardiovasc Interv ; 10(16): 1694-1704, 2017 08 28.
Article in English | MEDLINE | ID: mdl-28838480

ABSTRACT

OBJECTIVES: Atherosclerosis of iliac arteries is widespread. As inflow vessels, they are of great clinical significance and increasingly being treated by endovascular means. Most commonly, stents are implanted. BACKGROUND: So far, due to a lack of comparative data, no guideline recommendations on the preferable stent type, balloon-expandable stent (BE) or self-expanding stent (SE), have been issued. METHODS: In this randomized, multicenter study, patients with moderate to severe claudication from common or external iliac artery occlusive disease were assigned 1:1 to either BE or SE. The primary endpoint was binary restenosis at 12 months as determined by duplex ultrasound. Key secondary endpoints were walking impairment, freedom from target lesion revascularization (TLR), hemodynamic success, target limb amputation, and all-cause death. RESULTS: Six hundred sixty patients with 660 lesions were enrolled at 18 German and Swiss sites over a period of 34 months; 24.8% of the patients had diabetes and 57.4% were current smokers. The common iliac artery was affected in 58.9%. One hundred nine (16.5%) lesions were totally occluded and 25.6% heavily calcified. Twelve-month incidence of restenosis was 6.1% after SE implantation and 14.9% after BE implantation (p = 0.006). Kaplan-Meier estimate of freedom from TLR was 97.2% and 93.6%, respectively (p = 0.042). There was no between-group difference in walking impairment, hemodynamic success, amputation rate, all-cause death, or periprocedural complications. CONCLUSIONS: The treatment of iliac artery occlusive disease with SE as compared with BE resulted in a lower 12-month restenosis rate and a significantly reduced TLR rate. No safety concerns arose in both groups. (Iliac, Common and External [ICE] Artery Stent Trial; NCT01305174).


Subject(s)
Angioplasty, Balloon/instrumentation , Iliac Artery , Intermittent Claudication/therapy , Peripheral Arterial Disease/therapy , Stents , Aged , Amputation, Surgical , Angioplasty, Balloon/adverse effects , Angioplasty, Balloon/mortality , Exercise Tolerance , Female , Germany , Humans , Iliac Artery/diagnostic imaging , Iliac Artery/physiopathology , Intermittent Claudication/diagnostic imaging , Intermittent Claudication/physiopathology , Kaplan-Meier Estimate , Limb Salvage , Male , Middle Aged , Peripheral Arterial Disease/diagnostic imaging , Peripheral Arterial Disease/mortality , Peripheral Arterial Disease/physiopathology , Prospective Studies , Prosthesis Design , Recovery of Function , Recurrence , Risk Factors , Severity of Illness Index , Switzerland , Time Factors , Treatment Outcome , Ultrasonography, Doppler, Duplex , Vascular Patency , Walking
SELECTION OF CITATIONS
SEARCH DETAIL
...